Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol
2. 1,2-dipalmitoylphosphatidylglycerol
3. Dppg
1. 4537-77-3
2. Dppg
3. 1,2-dipalmitoylphosphatidylglycerol
4. Va9u6br3sb
5. Chebi:60724
6. [3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-hexadecanoyloxypropyl] Hexadecanoate
7. 3-(((2,3-dihydroxypropoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl Dipalmitate
8. 3-{[(2,3-dihydroxypropoxy)(hydroxy)phosphoryl]oxy}-2-(hexadecanoyloxy)propyl Hexadecanoate
9. 1,2-dipalmitoyl-phosphatidyl-glycerole
10. Unii-va9u6br3sb
11. Dipalmitoyl Phosphatidylglycerol
12. Starbld0008282
13. C16:0 Phosphatidylglycerol
14. Chembl2286758
15. Schembl13587396
16. Dl-dipalmitoylphosphatidylglycerol
17. Dtxsid70963375
18. C16:0 Pg
19. Db02043
20. Dipalmitoylphosphatidylglycerol, Dl-
21. Q27888734
22. Hexadecanoic Acid, 1,1'-(1-((((2,3-dihydroxypropoxy)hydroxyphosphinyl)oxy)methyl)-1,2-ethanediyl)ester
23. Hexadecanoic Acid, 1-((((2,3-dihydroxypropoxy)hydroxyphosphinyl)oxy)methyl)-1,2-ethanediyl Ester
| Molecular Weight | 723.0 g/mol |
|---|---|
| Molecular Formula | C38H75O10P |
| XLogP3 | 12.2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 40 |
| Exact Mass | 722.50978558 g/mol |
| Monoisotopic Mass | 722.50978558 g/mol |
| Topological Polar Surface Area | 149 Ų |
| Heavy Atom Count | 49 |
| Formal Charge | 0 |
| Complexity | 797 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 2 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
The results to date with CER-001 are consistent with the known pleiotropic effects of HDL, scavenging endotoxin, reversing the cytokine cascade and improving endothelial function.
Lead Product(s): CER-001,Dipalmitoylphosphatidylglycerol,Sphingomyelins
Therapeutic Area: Nephrology Brand Name: CER-001
Study Phase: Phase IIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 04, 2022
Lead Product(s) : CER-001,Dipalmitoylphosphatidylglycerol,Sphingomyelins
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results to date with CER-001 are consistent with the known pleiotropic effects of HDL, scavenging endotoxin, reversing the cytokine cascade and improving endothelial function.
Product Name : CER-001
Product Type : Protein
Upfront Cash : Inapplicable
July 04, 2022
Details:
CER-001 is the first-in-class bio-HDL mimetic that directly targets a key underlying metabolic defect of LCAT deficiency. The bio-HDL is one of the most advanced biomedicines and is a potential novel treatment for kidney diseases.
Lead Product(s): CER-001,Dipalmitoylphosphatidylglycerol,Sphingomyelins
Therapeutic Area: Rare Diseases and Disorders Brand Name: CER-001
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 29, 2022
Lead Product(s) : CER-001,Dipalmitoylphosphatidylglycerol,Sphingomyelins
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CER-001 is the first-in-class bio-HDL mimetic that directly targets a key underlying metabolic defect of LCAT deficiency. The bio-HDL is one of the most advanced biomedicines and is a potential novel treatment for kidney diseases.
Product Name : CER-001
Product Type : Protein
Upfront Cash : Inapplicable
March 29, 2022
Details:
ABIONYX has received authorization to launch a clinical RACERS trial (a RAndomized study comparing short-term CER-001 infusions at different doses to prevent Sepsis-induced acute kidney injury) with CER-001 in septic patients at high risk of developing acute kidney injury.
Lead Product(s): CER-001,Dipalmitoylphosphatidylglycerol,Sphingomyelins
Therapeutic Area: Nephrology Brand Name: CER-001
Study Phase: Phase IIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 23, 2020
Lead Product(s) : CER-001,Dipalmitoylphosphatidylglycerol,Sphingomyelins
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABIONYX has received authorization to launch a clinical RACERS trial (a RAndomized study comparing short-term CER-001 infusions at different doses to prevent Sepsis-induced acute kidney injury) with CER-001 in septic patients at high risk of developing a...
Product Name : CER-001
Product Type : Protein
Upfront Cash : Inapplicable
December 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
48
PharmaCompass offers a list of Dipalmitoylphosphatidylglycerol API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dipalmitoylphosphatidylglycerol manufacturer or Dipalmitoylphosphatidylglycerol supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dipalmitoylphosphatidylglycerol manufacturer or Dipalmitoylphosphatidylglycerol supplier.
PharmaCompass also assists you with knowing the Dipalmitoylphosphatidylglycerol API Price utilized in the formulation of products. Dipalmitoylphosphatidylglycerol API Price is not always fixed or binding as the Dipalmitoylphosphatidylglycerol Price is obtained through a variety of data sources. The Dipalmitoylphosphatidylglycerol Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Dipalmitoylphosphatidylglycerol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dipalmitoylphosphatidylglycerol, including repackagers and relabelers. The FDA regulates Dipalmitoylphosphatidylglycerol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dipalmitoylphosphatidylglycerol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Dipalmitoylphosphatidylglycerol supplier is an individual or a company that provides Dipalmitoylphosphatidylglycerol active pharmaceutical ingredient (API) or Dipalmitoylphosphatidylglycerol finished formulations upon request. The Dipalmitoylphosphatidylglycerol suppliers may include Dipalmitoylphosphatidylglycerol API manufacturers, exporters, distributors and traders.
Dipalmitoylphosphatidylglycerol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dipalmitoylphosphatidylglycerol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dipalmitoylphosphatidylglycerol GMP manufacturer or Dipalmitoylphosphatidylglycerol GMP API supplier for your needs.
A Dipalmitoylphosphatidylglycerol CoA (Certificate of Analysis) is a formal document that attests to Dipalmitoylphosphatidylglycerol's compliance with Dipalmitoylphosphatidylglycerol specifications and serves as a tool for batch-level quality control.
Dipalmitoylphosphatidylglycerol CoA mostly includes findings from lab analyses of a specific batch. For each Dipalmitoylphosphatidylglycerol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dipalmitoylphosphatidylglycerol may be tested according to a variety of international standards, such as European Pharmacopoeia (Dipalmitoylphosphatidylglycerol EP), Dipalmitoylphosphatidylglycerol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dipalmitoylphosphatidylglycerol USP).
